I
3.12
-0.09 (-2.96%)
| Penutupan Terdahulu | 3.21 |
| Jumlah Dagangan | 15,814 |
| Harga / Buku (P/B) | 33.86 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -41.44 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.13% |
| Nisbah Semasa (MRQ) | 1.90 |
| Aliran Tunai Operasi (OCF TTM) | -13.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.63 M |
| Pulangan Atas Aset (ROA TTM) | -122.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -259.00% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Indaptus Therapeutics, Inc. | Bercampur | Bercampur |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| INDP | - | - | - | 33.86 |
| SONN | 33 M | - | - | 2.07 |
| CDIO | - | - | - | 0.740 |
| REPL | - | - | - | 10.78 |
| ADXN | - | - | - | 1.30 |
| IFRX | - | - | - | 1.09 |
AISkor Stockmoo
| Nilai 35% | -0.8 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -0.8 |
| Masa 35% | 1.3 |
| AI Technical info | NA |
| Osilator Teknikal info | 0.5 |
| Purata Bergerak Teknikal info | 2.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Sentimen Berita info | NA |
| Persekitaran | ×0.79 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -23.9% |
| Persetujuan Tonggak | ×0.87 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | -4.5 |
| Skor Akhir | 0.12 |
|
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 36.87% |
| % Dimiliki oleh Institusi | 13.08% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 24 Sep 2026 | Yahoo Finance |
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better
Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%. |
| 13 Aug 2026 | Yahoo Finance |
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company"), a biotechnology company dedicated to immunotherapy research, today announced financial results for the second quarter and six months ended June 30, 2026, and provided a corporate… |
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |